Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06418724
What this trial is testing

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Who this might be right for
Locally Advanced Cutaneous Squamous Cell Carcinoma
Melanoma and Skin Cancer Trials Limited 27
Testing effectiveness (Phase 2)WithdrawnNCT00048087
What this trial is testing

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Active Not RecruitingNCT05870319
What this trial is testing

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Testing effectiveness (Phase 2)Study completedNCT00788957
What this trial is testing

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Colon CancerColorectal CancerGastrointestinal Cancer+2 more
NantBioScience, Inc. 177
Early research (Phase 1)Study completedNCT00040781
What this trial is testing

Gefitinib in Treating Children With Refractory Solid Tumors

Who this might be right for
Unspecified Childhood Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 45
Early research (Phase 1)Not Yet RecruitingNCT06585059
What this trial is testing

Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers

Who this might be right for
Advanced Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 20
Not applicableStudy completedNCT07267247
What this trial is testing

Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)Drug-Related Side Effects and Adverse Reactions (MeSH Term)Egfr Tyrosine Kinase Inhibitor+1 more
Taichung Veterans General Hospital 100
Early research (Phase 1)Study completedNCT00254384
What this trial is testing

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IA Lung Non-Small Cell Carcinoma AJCC v7Stage IB Lung Non-Small Cell Carcinoma AJCC v7+4 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Ended earlyNCT04971187
What this trial is testing

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 3
Not applicableUnknownNCT06081270
What this trial is testing

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer

Who this might be right for
Lung Cancer
University of Milano Bicocca 20
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Early research (Phase 1)Looking for participantsNCT06813365
What this trial is testing

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Who this might be right for
Nonsmall-cell Lung Cancer
Dizal Pharmaceuticals 300
Not applicableStudy completedNCT04105153
What this trial is testing

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Thoraxklinik-Heidelberg gGmbH 400
Testing effectiveness (Phase 2)WithdrawnNCT00570375
What this trial is testing

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
University of Cincinnati
Testing effectiveness (Phase 2)Looking for participantsNCT06992739
What this trial is testing

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFRMyelosuppression
The First Affiliated Hospital of Xiamen University 49
Not applicableStudy completedNCT06411093
What this trial is testing

Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors

Who this might be right for
ParonychiaEpidermal Growth Factor Receptor Inhibitor
Chang Gung Memorial Hospital 24
Large-scale testing (Phase 3)Looking for participantsNCT07100080
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 500
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Early research (Phase 1)Ended earlyNCT02342353
What this trial is testing

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small Cell Lung CancerNonsmall Cell Lung CancerCarcinoma, Non-Small-Cell Lung
Washington University School of Medicine 8
Testing effectiveness (Phase 2)Study completedNCT01449461
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Who this might be right for
Lymphoma, Large-Cell, AnaplasticCarcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 137
Next Page